Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ 136”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205 · cited 1×
“in keratinocytes to create a “danger signal” is unclear (51), but several possible molecular events may occur to activate resting dendritic APCs (52), followed by delivery of an antigenic signal”
BackgroundPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“ic inflammatory diseases, HMGB1 is also considered an important regulator (67).”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 10×
“The successful use of cyclosporin, which acts to block cytokine release, resulted in a paradigm shift away from epidermal keratinocytes to various immunocyte populations including T cell subsets and dendritic APCs.”
BackgroundInfluentialAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Cited by
Items 501–542 of 542
Vascular pattern under videodermatoscopy observation
Filosa, G., Angelis, R. D., & Bugatti, L. (2009) · Series in dermatological treatment · doi:10.3109/9781841847153.011
The Aetiopathogenesis of Psoriasis in 2014: An Update
Meglio, P. D., & Mak, R. K. H. (2014) · EMJ Dermatology · doi:10.33590/emjdermatol/10312377
Paradoxical onset of psoriasis after IL-6 receptor blockade
Ayala‐Fontanez, N. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
Pathogenesis of Psoriasis Vulgaris (the third part)
Suda, T., & Terui, T. (2006) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.68.656
IL-6 Signals Through pStat3 to Prevent Functional Immune Suppression by Human Regulatory T Cells
Goodman, W. A. (2010) · OhioLink ETD Center (Ohio Library and Information Network)
Brief Report - Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis
Sridhar, J., Desylva, P., & Singh, Y. (2006) · TSpace (University of Toronto)
Motaleb, A. A. A., Sayed, D. S., Morsy, H. A., Refaiy, A. E., El-Hagag, N. A. A., Gamal, Y. A., & Hussein, M. R. (2017) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000515463.44232.85
Kaur, R., Wani, A., Ganai, B., Akhtar, T., & Narang, T. K. (2018) · Egyptian Journal of Dermatology and Venerology · doi:10.4103/ejdv.ejdv_23_17
Le psoriasis vulgaire: de la pathogenèse au traitement
Yawalkar, N., & Braathen, L. R. (2006) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2006.05885
Edwards, C. K., Pedler, M. G., Yang, D. F., Fitzpatrick, J. E., Fujita, M., Jonscher, K. R., & Norris, D. A. (2012) · Psoriasis Forum · doi:10.1177/247553031218a00304
Mukai, M. M. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Evaluation of Contact Sensitivity in Patients with Psoriasis
Koryürek, Ö. M., Toğral, A. K., ŞAHİN, M., & Ekşioğlu, M. (2018) · Turkiye Klinikleri Journal of Dermatology · doi:10.5336/dermato.2018-61755
Update on Risankizumab for Psoriasis
Bares, J., & Lebwohl, M. (2019) · Current Dermatology Reports · doi:10.1007/s13671-019-0250-4
Veras, F. P. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2019.tde-10102018-101925
Deshmukh, M. D., Agiwal, P. S., Gugle, A. S., Kumavat, S., & Pawar, M. K. (2019) · MVP Journal of Medical Sciences · doi:10.18311/mvpjms/2018/v5i2/18268
Ahmed, H. B., Lal, D. M., Pirzado, M. S., Rashid, A., Anwar, I., & Malkani, S. (2019) · The Professional Medical Journal · doi:10.29309/tpmj/2019.26.11.692
Serum Level of Periostin and Cardiac Function in Patients with Psorasis
Bahrawy, M. S. E., Farg, S. I., El-Shimi, O. S., & El-Taweel, A. A. I. (2019) · Benha Journal of Applied Sciences · doi:10.21608/bjas.2019.187126
“It is characterized by periods of spontaneous remission and exacerbations that affect approximately 2-3% of the population worldwide [2].”
BackgroundRole of cluster of differentiation 93 in psoriasis
El-Batanony, E., Maraee, A., Bazid, H. A. S., & Gayed, E. M. A. E. (2021) · Menoufia Medical Journal · doi:10.4103/mmj.mmj_317_19
Association analysis of GAS5 polymorphisms and psoriasis
Ghafouri‐Fard, S., Tamizkar, K. H., Gholipour, M., Abak, A., Oskooei, V. K., Taheri, M. N., & Rakhshan, A. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101337
Burg, G., Geiges, M. L., Kempf, W., & Dummer, R. (2005) · Fortschritte der praktischen Dermatologie und Venerologie · doi:10.1007/3-540-28691-8_18
Skin: Immunological Defence Mechanisms
Nickoloff, B. J. (2007) · Wiley eBooks · doi:10.1002/9780470015902.a0001215.pub2
Self-citationSearch for potential biomarkers of inveterate dermatoses by means of proteomic analysis
BRATSEVA, Y. V., Moshkovsky, S. A., Znamenskaya, L. F., Kubanova, A. A., & Kubanov, A. A. (2010) · Vestnik dermatologii i venerologii · doi:10.25208/vdv887
“В развитии заболевания лежат активация в коже Т-лимфоцитов (преимущественно Т1-хелперов), а также гиперпролиферация кератиноцитов [18, 22].”
Kubanov, A. A., Frigo, N. V., Ротанов, С. В., HAYRULLIN, R. F., Znamenskaya, L. F., & Svishchenko, S. I. (2012) · Vestnik dermatologii i venerologii · doi:10.25208/vdv696
POSTERS SCORING AND MONITORING THE SEVERITY OF THE DISEASE
(2004) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2004.01166-2.x
Lebwohl, M., & Thompson, E. H. Z. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.050
Part I: Interactive case: Psoriasis
Gladwell, T. D. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1647
Kolerova, A. V., Blinova, E. A., Va, K., & Sergeeva, I. G. (2022) · Russian Journal of Clinical Dermatology and Venereology · doi:10.17116/klinderma202221021194
Treating Psoriasis: What Is New About Fumaric Acid Esters?
Pedder, A. (2018) · European Medical Journal · doi:10.33590/emj/10314355
Effects of retinoic acid on immunity and inflammation in patients with Psoriasis vulgaris
Liu, Y., Li, M., & Ding, Z. (2023) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i7.16
“Besides, the abnormal proliferation and differentiation of keratinocytes can be observed under the microscope, and more infiltrating immune cells appear in the epidermis and dermis [1].”
BackgroundA pikkelysömör pszichológiai vonatkozásai
Kohutics, K., & Rigó, A. (2023) · Mentálhigiéné és Pszichoszomatika · doi:10.1556/0406.2023.00040
Hussein, A. P. D. T. A., & Khalaf, H. Y. (2022) · journal of the college of basic education · doi:10.35950/cbej.v21i90.6942
Hussein, A. P. D. T. A., & Mohsen, A. J. (2022) · journal of the college of basic education · doi:10.35950/cbej.v21i91.7391
Formulation, Optimization and Evaluation of Nanoemulsion for the treatment of psoriasis
Chandrakar, K., & Tiwari, S. P. (2025) · International Journal of Pharmaceutical Research and Applications · doi:10.35629/4494-1003189234
Transethosomal Hydrogel: A Novel Nanocarrier Approach for Enhanced Psoriasis Treatment
Mutha, J., Koka, S. S., Dwivedi, S., Sharma, P. K., Sharma, R. K., Gupta, A. G., & Darwhekar, G. N. (2025) · European journal of parenteral & pharmaceutical sciences · doi:10.37521/ejpps30214 · Cited by 1
Transfer Learning Approach for Assessment of Psoriasis Erythema Severity
Kovvuru, A. K., Londhe, N. D., Raj, R., & Sonawane, R. S. (2025) · International Conference on Computer Vision and Computational Intelligence (CVCI) · doi:10.1145/3744725.3744732
Leveraging Channel Slicing and Overcomplete Network for Scaliness Estimation in Psoriasis Lesion
Kovvuru, A. K., Londhe, N. D., & Sonawane, R. S. (2025) · International Conference on Biomedical Engineering and Sustainable Healthcare (ICBMESH) · doi:10.1109/icbmesh66209.2025.11182226
Pathophysiology and Molecular Basis of Psoriasis
Wilson, K., Tanvi, Goyal, R., Gupta, S., Dora, C. P., & Garima (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898812737126010005
Nanostructured Lipid-Based Pharmacotherapy for the Management of Psoriasis
Kumar, M., Kashyup, D., Arora, N., Kumar, A., & Kumar, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898812737126010012
Parny, M. (2020) · theses.fr (ABES) · doi:10.70675/43001866z792bz4ef1z9593ze927a52316f6
Pathak, V. K., Singh, I., Sharma, R., Turankar, R. P., & Sengupta, U. (2026) · Scientific Reports · doi:10.1038/s41598-026-54875-5
“Furthermore, the frequent occurrence of keratinization abnormalities such as keratosis in tuberculoid leprosy during T1R supports the role of keratin directed immune responses in disease pathogenesis 13,14,39 .”
Metadata
- Authors
- Nickoloff, B. J., & Nestle, F. O.
- Affiliations
- Loyola University Medical Center (US)
- University of Zurich (CH)
- Corresponding author
- Nickoloff, Brian J.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-06-15
- Volume
- 113
- Issue
- 12
- Pages
- 1664-1675
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC420513
- OpenAlex
- W2024387258
- Cited by
- 544
- References
- 110
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 18 · 2020: 10 · 2019: 23 · 2018: 18 · 2017: 17 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 29 · 2012: 27
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR40065, R01AR040065)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, immunopathogenesis, T cells, immunological synapse, cytokine signaling pathways, xenotransplantation model, targeted therapy, psoriasis genetics, chronic skin inflammation, psoriatic arthritis
- MeSH terms
- Animals, Dermatologic Agents, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Psoriasis, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.